← Back to patent-cliff list
AK-1830
Tier C — Watch / tradeAK-1830
Array Biopharma
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Trk-A
Indications (approved)：Low back pain
Regional status
US
-
EU
-
China
-
Japan
Phase II
2020-08-26
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of AK-1830?
Approved indications include: Low back pain.
When does the AK-1830 patent expire?
No public expiry year is available for AK-1830 yet; this page updates once verified.
How do I get a quote for AK-1830 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06